The ß-amyloid peptide in Alzheimer's disease decreases adhesion of vascular muscle cells to the basement membrane
Mok, Su San, Losic, Dusan, Barrow, Colin J., Turner, Bradley J., Masters, Colin L., Martin, Lisandra L. and Small, David H. 2006, The ß-amyloid peptide in Alzheimer's disease decreases adhesion of vascular muscle cells to the basement membrane, Journal of neurochemistry, vol. 96, no. 1, pp. 53-64.
Attached Files
(Some files may be inaccessible until you login with your Deakin Research Online credentials)
Name
Description
MIMEType
Size
Downloads
Title
The ß-amyloid peptide in Alzheimer's disease decreases adhesion of vascular muscle cells to the basement membrane
Cerebral amyloid angiopathy (CAA) is a major feature of Alzheimer's disease pathology. In CAA, degeneration of vascular smooth muscle cells (VSMCs) occurs close to regions of the basement membrane where the amyloid protein (Aβ) builds up. In this study, the possibility that Aβ disrupts adhesive interactions between VSMCs and the basement membrane was examined. VSMCs were cultured on a commercial basement membrane substrate (Matrigel). The presence of Aβ in the Matrigel decreased cell-substrate adhesion and cell viability. Full-length oligomeric Aβ was required for the effect, as N- and C-terminally truncated peptide analogues did not inhibit adhesion. Aβ that was fluorescently labelled at the N-terminus (fluo-Aβ) bound to Matrigel as well as to the basement membrane heparan sulfate proteoglycan (HSPG) perlecan and laminin. Adhesion of VSMCs to perlecan or laminin was decreased by Aβ. As perlecan influences VSMC viability through the extracellular signal-regulated kinase (ERK)1/2 signalling pathway, the effect of Aβ1–40 on ERK1/2 phosphorylation was examined. The level of phospho-ERK1/2 was decreased in cells following Aβ treatment. An inhibitor of ERK1/2 phosphorylation enhanced the effect of Aβ on cell adhesion. The studies suggest that Aβ can decrease VSMC viability by disrupting VSMC–extracellular matrix (ECM) adhesion.
Language
eng
Field of Research
030499 Medicinal and Biomolecular Chemistry not elsewhere classified 060105 Cell Neurochemistry